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1. INTRODUCTION
among the drug delivery system, oral drug delivery is far 
the most popular route of drug delivery due to its patient 
compliance, ease of administration and cost effective 
manufacturing process (1). as most of the drugs are 
absorbed from the stomach or the upper part of the GI 
tract, novel oral controlled dosage form that is retained in 
the stomach is been a center of interest among industrial and 
academic researchers. One of the most popular approaches 
for attaining prolonged and predictable drug delivery in the 
stomach is gastro retentive drug delivery system (GRDDS) 
(2, 3). Generally, GRDDS is a controlled release drug delivery, 
which can significantly prolong the gastric residence time, 
which will increase the efficacy and bioavailability of drugs in 
the stomach. among the various approaches of the GRDDS, 
floating drug delivery system (FDDS) has attained a great 
interest recently (4). Floating system involves the gas forming 
agent that helps in keeping the formulation in buoyant 
state and hence avoids its passage stomach facilitating the 
controlled release of drug from formulation (5, 6).
Carbamazepine (CBz) is a drug widely used as antiepileptic 
in the therapy of psychomotor seizures and trigeminal 
neuralgia for its anticonvulsant and antineuralgic effects. 
Its popularity is related to its several beneficial properties, 
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including efficacy in controlling different types of seizures 
(7). But CBz is poorly soluble in water (170 mg/L at 24ºC) 
with erratic oral absorption and bioavailability less than 70%. 
Gastric retention can improve the bioavailability for such a 
poorly water soluble drug. Thus prolonged gastric retention 
by GRFDDS improves bioavailability, reduces drug waste, 
and improves solubility for drugs that are less soluble in a 
high ph environment of small intestine as Carbamzepine is 
well absorbed in the stomach and upper portion of the small 
intestine.
although several polymers like hPMC K4M, ethyl 
cellulose etc have been studied to formulate Carbamazepine 
gastroretentive floating drug delivery system (8) to improve 
its bioavailability, the objective of the present study was 
undertaken to develop a FDDS containing Carbamazepine 
as a model drug incorporated with two hydrophilic polymer 
Methocel K4M and Carbopol 971, and to observe the effect 
of these polymers and critical parameter on floating and 
drug release behavior of the system and selecting the best 
formulation based on optimizing techniques using evaluation 
parameters like floating lag time, total floating time and drug 
release profile.
2. MATERIALS AND METHODS
2.1   Materials
In this study Carbamazepine was used as a model drug 
obtained as a generous sample from Drug International 
Ltd, Bangladesh. Polymer Methocel K4M, Carbopol 971 
were procured from BaSF, Bangladesh Limited. Citric acid 
Monohydrate, crospovidone, avicel ph 101, Purified Talc 
and Magnesium stearate were also obtained as gift sample 
from university of asia Pacific (uaP), Bangladesh. all other 
chemicals used were of analytical reagent grade and distilled 
water was used throughout the experiments.
2.2   Preparation of floating matrix tablet
Floating tablets of Carbamazepine were prepared by 
direct compression method. The composition of various 
formulations is shown in Table 1. The active ingredient 
and other excipients were weighed accurately for twenty 
five tablets according to the formulations and then blended 
together geometrically in a mortar pestle until homogenized. 
The granules were then sieved through mesh 40. Finally the 
granules were weighed to adjust the final weight of individual 
tablet considering its loss during operational handling. The 
granules were compacted into tablets by direct compression 
at fixed compression force (5 tons) for specific period of time 
(2 min) in the Perkin-elmer laboratory hydraulic press. The 
amount of active ingredient was 100 mg and the total weight 
of the tablets was 500 mg for all of the 12 formulations. 
Formulated tablets were stored in airtight film container 
at room temperature (25ºC to 30ºC) until further study. 
This method of tablet preparation has been carried out in 
accordance with our previously published papers (9-11) that 
provided reproducible experimental results in terms of in-
vitro release.
Table 1. Formulation of Carbamazepine with two different polymers
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12
Carbamazepine 100 100 100 100 100 100 100 100 100 100 100 100
Methocel K4M 80 100 120 140 160 200 - - - - - -
Carbopol 971 - - - - - - 80 100 120 140 160 200
nahCO3 50 50 50 50 50 50 50 50 50 50 50 50
Citric acid 50 50 50 50 50 50 50 50 50 50 50 50
Crospovidone 20 20 20 20 20 20 20 20 20 20 20 20
avicel Ph 102 190 170 150 130 110 70 190 170 150 130 110 70
Mg Stearate 5 5 5 5 5 5 5 5 5 5 5 5
Purified Talc 5 5 5 5 5 5 5 5 5 5 5 5
Total 500 500 500 500 500 500 500 500 500 500 500 500
*all the amounts are expressed in mg
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2.3   Drug content and physical characterization
The drug content of the formulated tablets was estimated 
using 50% methanol solution as a solvent, and the sample was 
analyzed using double beam uV-Visible spectrophotometer 
(uV-1800, Shimadzu, Japan) at 284 nm. all the formulated 
tablets were evaluated for hardness, friability, thickness, 
weight variation with regards their specification.
2.4   In vitro buoyancy study
The in vitro buoyancy was determined by floating lag time 
and the duration of floating of the developed tablets, Briefly, 
the tablets were placed in a 100 mL beaker containing 0.1n 
hCl. (ph 1.2). The media was kept in stagnant condition and 
the temperature was maintained at 370 C. The time required 
for the tablet to rise to the surface and float was determined 
as floating lag time and the floating durations were visually 
observed (12, 13)
 
2.5   Swelling index
For the determination of swelling index, tablet from all 
formulations was placed in a beaker containing 100 mL of 
0.1n hCl at room temperature. after each hour the tablet 
was removed from beaker and weighed again up to 5 hours 
(14). Tablets were removed carefully from the medium to 
ensure no loss of surface materials and excess surface water 
was wiped out with a tissue paper. The percentage swelling 
index was calculated using the following formula:
                       
                  
Where, Wt = Weight of tablet at time t; Wo = Initial weight 
of tablet
2.6   In-vitro drug release studies
The in-vitro release studies of the carbazmazepine from 
formulated tablets were performed using uSP type-IΙ 
apparatus (paddle method) for 8 hours at a stirring rate of 
75 rpm (8, 15). The dissolution medium consisted of 0.1 n 
hCl acid media of ph 1.2, 900 mL, maintained at 37°C ± 
0.5°C. an aliquot (5 mL) was withdrawn at specific time 
intervals which replaced by equivalent amount of media to 
maintain complete sink condition. The percent drug release 
was determined by uV-visible spectrophotometer (uV-
1800, Shimadzu, Japan) at 284 nm. The release studies were 
conducted in triplicate.
2.7  Analysis of release data
To analyze the release kinetics of drug from the formulated 
floating matrix tablets, the obtained in vitro release data 
were fitted to different equations like zero order, first order, 
higuchi’s release and Korsmeyer-Peppas’ models (16). The 
obtained dissolution data were also treated according to the 
well-known exponential equation, which is often used to 
describe the drug release behavior from polymeric systems 
introduced by Korsmeyer-Peppas et. al (16).
Mt / M∞ = k tn
Where, Mt is the amount of drug release at time t, M∞ is 
the amount of drug release after infinite time; k is a release 
rate constant incorporating structural and geometric 
characteristics of the tablet and n is the diffusional exponent 
indicative of the mechanism of drug release. a value of n 
= 0.45 indicates Fickian (case I) release, > 0.45 but < 0.89 
for non-Fickian (anomalous) release and > 0.89 indicates 
super case II type of release. Case II generally refers to the 
erosion of the polymeric chain and anomalous transport 
(non-Fickian) refers to a combination of both diffusion and 
erosion controlled-drug release (17).
Mean dissolution time (MDT) was calculated from 
dissolution data using the following equation (Mockel and 
Lippold) (18).
MDT = (n / n+1) k-1/n
Where, n is the release exponent and k is the release rate 
constant.
2.8 Statistical analysis
To address the effect of polymer type on drug release, student 
t- test used applied. 
p<0.05 considered as statistically significant.
3. RESULTS AND DISCUSSION
3.1   Physical characterization and drug content of floating 
tablets
Table 2 is presented the values of physical parameters 
(thickness, diameter, hardness and friability), weight 
uniformity and drug content of all the formulated tablets. 
The thickness and diameter of the tablets were ranged from 
3.04 ± 0.04 mm to 3.51 ± 0.02 mm and 13.29 ± 0.02 mm to 
13.54 ± 0.01 mm, respectively. hardness of the tablets of all 
the formulations ranged from 12.66 ± 0.19 kgf to 26.93 ± 0.44 
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kgf. In the present study, the percentage friability for all the 
formulations was below 1% w/w, indicating that the friability 
was within the prescribed limits. The weight variations of 
prepared tablets complied with the BP Pharmacopoeial 
specifications (19). The drug content in all the batches of 
carbamazepine floating tablet was found within the range of 
95-105% and this ensured the uniformity of drug content. 
So, all the formulated floating tablets showed acceptable 
physicochemical properties and complied with British 
Pharmacopoeial specifications of label content. 
Table 2. Physicochemical properties of carbamazepine floating tablets of different formulations
Formulation Weight variation (mg) * Thickness (mm)** Diameter (mm)** Hardness (Kf)* Friability (%)* Drug content** (%)
F-1 490.13±0.45 3.15±0.02 13.5±0.02 12.66±0.19 0.09±0.04 100.68±0.10
F-2 500.63±0.05 3.51±0.02 13.54±0.01 13.17±0.47  0.22±0.02 103.37±0.01
F-3 498.43±0.17 3.35±0.04 13.50±0.02 15.5±0.37  0.32±0.10 99.08±0.35
F-4 500.15±0.08 3.34±0.02 13.46±0.02 15.69±0.46  0.34±0.00 99.61±0.19
F-5 500.00±0.08 3.49±0.01 13.48±0.03 16.6±0.32  0.27±0.04 100.52±0.27
F-6 503.63±0.19 3.32±0.01 13.45±0.02 20.26±0.29 0.28±0.04 103.40±0.15
F-7 485.23±0.12 3.07±0.09 13.33±0.02 21.56±0.51 0.30±0.02 100.36±0.02
F-8 487.02±0.10 3.05±0.04 13.29±0.04 23.46±0.30 0.19±0.02 95.43±0.89
F-9 482.73±0.18 3.04±0.04 13.29±0.02 24.96±0.60 0.19±0.09 95.29±0.55
F-10 506.42±0.13 3.19±0.04 13.42±0.03 26.20±0.71 0.22±0.04 98.47±0.41
F-11 490.57±0.09 3.10±0.05 13.37±0.03 26.93±0.44 0.33±0.02 98.20±0.65
F-12 495.57±0.05 3.11±0.04 13.36±0.04 26.87±0.44 0.26±0.06 96.90±0.82
The values are expressed as mean ± SeM; * and ** indicates n=10 and n=3 respectively 
3.2   In vitro buoyancy study
In-vitro buoyancy study was carried out for determining 
floating lag time and floating duration of tablet by placing 
tablet in 100 mL beaker containing 0.1 n hCl. In the present 
study, floating lag time of 12 formulations was found to be 
in the range of 4.12 to 136.2 sec and floating duration was 
found to be in the range of 6 to 18 h. It was also observed that 
buoyancy lag time is elevated for the formulations containing 
small amount of retardant polymer like Methocel K4M and 
total floating time is improved when the amount of Methocel 
K4M is gradually increased (Table 3). But buoyancy lag time 
is elevated for the formulation containing small amount of 
retardant polymer like Carbomer 971 and total floating time 
is reduces when the amount of Carbomer 971 is gradually 
increased (Table 3). There was an increase in the buoyancy 
lag time which could be attributed to the fact that tablets 
containing low viscosity Methocel K4M swell rapidly than 
tablets with high viscosity Carbomer 971. also higher 
floatation time of these tablets causes slower CO2 release 
because of the presence of the effervescent agents within the 
Methocel matrix.
Table 3. In-vitro buoyancy study of formulations containing 
Methocel K4M and Carbopol 971
Formulation Buoyancy lag time 
(sec)
Total floating time 
(hrs)
F-1 4.12 >  8
F-2 7.31 >  9
F-3 6.25 >  11
F-4 6.24 >  12
F-5 7.31 >  14
F-6 20.31 >  18
F-7 81.2 >  12
F-8 136.2 >  10
F-9 94.5 >  10
F-10 95.1 >  8
F-11 73.1 >  6
F-12 87.2 >  6
3.3   Swelling index
Swelling of tablet involves the incorporation of a liquid 
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resulting in an increase in tablet density. Liquid uptake by 
the particles may be due to the saturation of capillary spaces 
within the particles or hydration of macromolecule. The 
liquid enters the particles through pores and bind to large 
molecule; breaking the hydrogen bond and resulting in the 
swelling of particle. The extent of swelling was measured 
in terms of weight gain by the tablet.  Swelling index of 
formulations F7 to F12 containing polymer Carbomer 971 
was found to be more than formulations F1 to F6 containing 
polymer Methocel K4M (Table 4). From the results of swelling 
study it is clear that the percentage swelling increased as the 
time passes because the high viscosity polymer (Carbomer 
971) absorbed more water due to its hydrophilic nature than 
low viscosity polymer (Methocel K4M) and swell.
Table 4. Swelling index study of formulations containing Methocel K4M and Carbopol 971
Formulation
Swelling Index (%)
1h 2 h 3 h 4 h 5 h
F-1 22.51 35.88 44.01 56.33 63.82
F-2 16.30 34.55 43.68 64.12 80.06
F-3 15.86 34.04 43.13 63.50 79.38
F-4 63.19 82.38 90.65 97.63 97.97
F-5 75.00 97.19 99.20 104.10 105.10
F-6 64.03 97.62 107.57 119.55 120.17
F-7 59.59 71.93 85.50 95.59 116.07
F-8 80.76 103.68 105.76 110.81 111.84
F-9 71.47 86.23 100.60 114.47 142.32
F-10 71.33 85.73 101.25 115.72 148.61
F-11 72.44 91.79 112.85 131.10 166.80
F-12 77.43 97.96 114.26 144.40 169.65
3.4   Release kinetic studies
The dissolution data of all formulations were fitted to 
various mathematical models such as zero-order, first-order, 
higuchi’s, Korysmeyer and Peppas’ model to know which 
mathematical model will best fit for the obtained release 
profile. The cumulative percentage of drug release after 8 
hours of all formulations and the release parameters of all 
formulations are presented in Table 5. The release profile of 
promising batch, F4, fitted best to zero order with r2 value of 
0.998 (Figure 1). Based on the ‘n’ values ranging from 0.45 < 
n < 0.89 the drug release was found to follow anomalous or 
non-Fickian and Case II type release. This value indicates a 
coupling of the diffusion and erosion of the polymeric chain 
mechanism and the drug release was controlled by more 
than one process. This finding was in accordance with other 
reported works (20, 21).
Table 5. Cumulative percentage release (CPR) and release kinetics parameter of formulated floating tablets of CBz
Formulation CPR*
Zero order First order Higuchi’s Korsmeyar-Peppas’
R2 R2 R2 R2       n
F1 81.09 ± 1.19 0.781 0.92 0.946 0.946 0.459
F2 75.21 ± 1.17 0.864 0.965 0.983 0.993 0.471
F3 63.99 ± 1.07 0.908 0.971 0.997 0.998 0.465
F4 45.97 ± 1.28 0.998 0.996 0.941 0.994 0.838
F5 44.32 ± 1.17 0.988 0.972 0.895 0.972 0.839
F6 34.01 ± 1.01 0.986 0.992 0.971 0.994 0.668
F7 19.23 ± 2.90 0.976 0.982 0.976 0.995 0.798
F8  21.29 ± 1.22 0.956 0.997 0.956 0.994 0.762
F9 16.70 ± 3.03 0.964 0.996 0.964 0.999 0.789
F10   19.84 ± 1.07 0.966 0.994 0.966 0.997 0.841
F11  18.94 ± 0.95 0.963 0.996 0.963 0.998 0.894
F12   18.69 ± 1.18 0.995 0.997 0.954 0.996 0.914
 *CPR of drug after 8 hours, The values are expressed as mean ± SeM (n=3); 
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Figure 1. Dissolution release model of carbamazepine floating 
tablets containing (a) Methocel K4M and (b) Carbopol 971 
In this present study, two polymers Methocel K4M and 
Carbopol 971 were used in formulated CBz floating tablets 
to evaluate the effect on release profiles due to the polymer 
type. Methocel is a hydrophilic polymer and most widely 
used for controlled-release drug formulations and carbopols 
are synthetic high-molecular-weight polymers of acrylic acid 
and they are readily water-swellable polymers. 
The release of drug from Methocel K4M based floating 
tablets was greater than Carbopol based tablets. In case of 
both polymers, drug release decreased with the increase 
of concentration of polymer i.e higher the polymer 
concentration lowers the drug release. Between these two 
polymers, Carbopol 971 was statistically more effective 
(p<0.05) to retard the drug release than Methocel K4M. This 
could be explained due to the formation of more viscous 
layer (gel layer) in carbopol containing formulation upon 
exposure to aqueous medium by undergoing rapid hydration 
and chain relaxation and this gel layer acts as the barrier 
to release of drug and as a result drug release was more 
prolonged (Figure 2). The data revealed that, T25%, T50% and 
T75% values were altered due to the change of the quantity 
of Methocel K4M and Carbopol 971 in the floating tablets 
(Table 6). In all these formulations the values of T50% and T75% 
are larger for those formulations that contain larger quantities 
of Methocle K4M and Carbopol 971. This observation draws 
an important conclusion that the increase of Methocle K4M 
and Carbopol 971 content causes the decrease of rate and 
extent of CBz release. Carbopol 971 containing formaulation 
showed higher T50% values than that of Methocel K4M based 
formulation. 
Figure 2. Comparison of drug release rate at different 
concentrations (20% and 40%) of Methocel K4M and 
Carbopol 971.
Mean Dissolution Time (MDT) value is used to characterize 
the drug release rate from the dosage form and the retarding 
efficacy of the polymer. a higher value of MDT indicates 
a higher drug retarding ability and vice-versa. The MDT 
value was found to below for formulation F2 and high for 
formulation F8 (Table 6). In other words, the formulations 
containing higher percentage of polymer exhibited a 
higher value of MDT.  MDT values for Carbopol 971 based 
matrix supported the notion of retarding drug release more 
effectively than that of Methocel K4M based matrix.
Table 6. Required time for 25, 50, 75 percentage of drug 
release and mean dissolution time 
Formulations T25% T50% T75% MDT (hr)
F1 0.621 1.512 2.402 5.53
F2 0.776 1.786 2.796 5.08
F3 1.075 2.215 3.354 6.89
F4 1.874 3.352 4.829 9.57
F5 2.021 3.590 5.158 11.04
F6 2.341 4.430 6.518 17.90
F7 3.681 7.068 10.454 25.87
F8 4.435 8.531 12.628 38.03
F9 3.534 6.737 9.940 25.27
F10 3.734 7.127 10.519 24.60
F11 3.926 7.503 11.079 26.06
F12 4.010 7.633 11.255 22.98
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4. CONCLUSION
Swellable/floatable in-vitro buoyancy system for 
gastroretentive drug delivery has been developed using 
hydrophilic polymer Methocle K4M and Carbopol 971. The 
study revealed that both the polymer (Methocel K4M and 
Carbopol 971) has the capacity to retard the drug release 
from matrix in a concentration dependent fashion. Carbopol 
971 has the grater ability to retard the drug release than that 
of Methocel K4M. This phenomenon may be governed by the 
swelling properties of the polymers. Carbopol 971 showed 
the more swelling capacity than that of Methocel K4M. along 
with the retardant ability of drug release, both the polymer 
showed a considerable potential of its use as matrix former 
for floating drug delivery system. Drug was diffused out from 
the matrix with an anomalous non Fickian fashion.
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tabletlerinin formülasyonu ve in vitro değerlendirilmesi
ÖZ
Bu çalışmanın amacı, etken madde olarak karbamazepin 
içeren midede kalış süresini uzatan yüzen bir model tablette 
Metosel K4M and Karbomer 971 gibi hidrofilik polimerlerin 
etkinliklerinin değerlendirilmesidir. Polimerlerin etkinlikleri; 
fiziksel özellikleri, şişme özellikleri, yüzme yetenekleri ve 
ilaç salım profilleri açısından değerlendirilmiştir. Tabletlerin 
formülasyonlarına bağlı olarak yüzmeye başlama öncesindeki 
gecikme süreleri 4-136 saniye, toplam yüzme süreleri 6-18 
saat olarak bulunmuştur. Tabletlerden etken madde salımı 
8 saatlik bir zaman dilimi için çalışılmıştır. Simulasyon ile 
oluşturulan farklı ilaç salım kinetik modelleri ile yapılan 
çalışmalar sonucunda; hazırlanan bütün formülasyonların ilaç 
salım özelliklerinin özdeş olmadığı veya Fick yasasına uymadığı 
tespit edilmiştir. Karbopol 971’in, Metosel K4M’ye kıyasla daha 
yüksek şişme kapasitesine sahip olması nedeniyle ilaç salım 
süresini daha etkili şekilde uzattığı tespit edilmiştir.
Anahtar kelimeler: Karbamazepin, Metosel K4M, Karbopol 
971, yüzebilme özelliği, GRDDS.
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